Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Amylyx Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Amylyx Pharmaceuticals, Inc.

AMLX

Amylyx Pharmaceuticals, Inc.

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative and endocrine diseases with high unmet medical needs. Its pipeline includes investigational drugs like avexitide, a GLP-1 receptor antagonist targeting hyperinsulinemic hypoglycemia, and AMX0035, a combination therapy addressing cellular dysfunction in rare neurodegenerative disorders. Amylyx focuses on rigorous clinical development, proprietary technology, and targeting underserved patient populations through regulatory pathways and intellectual property protection.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Amylyx Pharmaceuticals, Inc.

1
1
Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals Reports $41.3 Million Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals Reports No Product Revenue and Significant Decrease in Operating Expenses for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals Reports No Revenue and Improved Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals Reports $41.4 Million Net Loss in Q2 2025, Focuses on Clinical Pipeline

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals Reports No Product Revenue and Significant Loss Reduction in Latest 10-Q

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals Reports $301.7 Million Net Loss for 2024 Following Product Withdrawal

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals Reports Significant Financial Challenges, Decline in Product Revenue, and Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments